Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AIM ImmunoTech (AIM) Retained Earnings (2018 - 2025)

Historic Retained Earnings for ImmunoTech (AIM) over the last 11 years, with Q3 2025 value amounting to -$436.6 million.

  • ImmunoTech's Retained Earnings fell 374.23% to -$436.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$436.6 million, marking a year-over-year decrease of 374.23%. This contributed to the annual value of -$426.8 million for FY2024, which is 422.95% down from last year.
  • As of Q3 2025, ImmunoTech's Retained Earnings stood at -$436.6 million, which was down 374.23% from -$433.3 million recorded in Q2 2025.
  • ImmunoTech's Retained Earnings' 5-year high stood at -$389.1 million during Q2 2023, with a 5-year trough of -$436.6 million in Q3 2025.
  • Over the past 3 years, ImmunoTech's median Retained Earnings value was -$419.0 million (recorded in 2024), while the average stood at -$417.6 million.
  • Per our database at Business Quant, ImmunoTech's Retained Earnings crashed by 720.74% in 2024 and then plummeted by 366.17% in 2025.
  • ImmunoTech's Retained Earnings (Quarter) stood at -$409.5 million in 2023, then fell by 4.23% to -$426.8 million in 2024, then fell by 2.29% to -$436.6 million in 2025.
  • Its last three reported values are -$436.6 million in Q3 2025, -$433.3 million for Q2 2025, and -$430.5 million during Q1 2025.